Alnylam Pharmaceuticals Are Trading Higher Amid Possible Continued Strength After the Company Yesterday Announced Topline Results From Its HELIOS-B Phase 3 Study of Vutrisiran. Also, Multiple Firms Raised Their Respective Price Targets on the Stock.
Alnylam Pharmaceuticals Are Trading Higher Amid Possible Continued Strength After the Company Yesterday Announced Topline Results From Its HELIOS-B Phase 3 Study of Vutrisiran. Also, Multiple Firms Raised Their Respective Price Targets on the Stock.
阿里拉姆製藥目前正在交易高位，可能會繼續保持強勁勢頭，因爲該公司昨天宣佈了Vutrisiran第3期HELIOS-B研究的最新結果。此外，多家公司將它們各自的股票價格目標提高了。
Alnylam Pharmaceuticals Are Trading Higher Amid Possible Continued Strength After the Company Yesterday Announced Topline Results From Its HELIOS-B Phase 3 Study of Vutrisiran. Also, Multiple Firms Raised Their Respective Price Targets on the Stock.
阿里拉姆製藥目前正在交易高位，可能會繼續保持強勁勢頭，因爲該公司昨天宣佈了Vutrisiran第3期HELIOS-B研究的最新結果。此外，多家公司將它們各自的股票價格目標提高了。
譯文內容由第三人軟體翻譯。
以上內容僅用作資訊或教育之目的，不構成與富途相關的任何投資建議。富途竭力但無法保證上述全部內容的真實性、準確性和原創性。